<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477397</url>
  </required_header>
  <id_info>
    <org_study_id>SMART2014</org_study_id>
    <nct_id>NCT02477397</nct_id>
  </id_info>
  <brief_title>Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD</brief_title>
  <official_title>Effectiveness of Single Inhaler Maintenance and Reliever Therapy With Spiromax® Budesonide/Formoterol (SMART) Versus Fixed Dose Treatment With Diskus® Fluticasone/Salmeterol in Patients With a Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to investigate the effects of symptom-driven maintenance and reliever therapy in COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide&#xD;
      and its morbidity and mortality are still rising. A symptom-driven maintenance and reliever&#xD;
      therapy (SMART) with budesonide/formoterol is a frequently used treatment strategy in asthma.&#xD;
      Several studies have shown that the SMART approach effectively reduces the number of asthma&#xD;
      exacerbations when compared to a fixed maintenance dose of, e.g. fluticasone/salmeterol. In&#xD;
      addition, larger improvements in lung function and symptoms have been observed in asthma&#xD;
      patients with the SMART approach. Thus far, no studies have investigated the efficacy of the&#xD;
      SMART approach in patients with COPD. The investigators hypothesize that SMART treatment with&#xD;
      budesonide/formoterol will be more effective than fluticasone/salmeterol fixed dose treatment&#xD;
      in COPD.&#xD;
&#xD;
      Objective: This research proposal aims to investigate the efficacy of the SMART approach with&#xD;
      budesonide/fomoterol versus fixed dose treatment with fluticasone/salmeterol in patients with&#xD;
      COPD.&#xD;
&#xD;
      Study design: This will be a randomized, parallel 2-arm, open-label, multi-centre study.&#xD;
&#xD;
      Study population: A total of 260 COPD patients will be included with a smoking history of &gt;10&#xD;
      pack years, an FEV1 &lt;80% predicted either or not using inhaled corticosteroids and having had&#xD;
      at least one COPD exacerbation during the 2 years prior to inclusion.&#xD;
&#xD;
      Intervention: COPD patients will be randomized to one of the following two treatment groups:&#xD;
&#xD;
      A: One year Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily +&#xD;
      Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 inhalations daily.&#xD;
&#xD;
      B: One year Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol&#xD;
      100 μg as needed with a maximum of 8 inhalations daily.&#xD;
&#xD;
      Main study endpoints/objectives: The primary endpoint is the reduction in number of COPD&#xD;
      exacerbations requiring treatment with oral prednisolone).&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: This study has no specific benefits for the participating patients. The study&#xD;
      also has no major risks. Minor risks for participants in this study are:&#xD;
&#xD;
        -  Nasal epithelium collection may cause a temporary nose bleed.&#xD;
&#xD;
        -  Blood collection may cause bruising.&#xD;
&#xD;
        -  All drugs may cause side effects. The combination treatments with an inhaled&#xD;
           corticosteroid and long-acting β2-agonist: budesonide/formoterol and&#xD;
           fluticasone/salmeterol are medicinal products that have been on the market for many&#xD;
           years in many countries and they are often prescribed both in asthma and COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with increase in symptoms of dyspnea, cough, sputum production</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function FEV1</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cell differential counts in blood</measure>
    <time_frame>1 year</time_frame>
    <description>Inflammation</description>
  </other_outcome>
  <other_outcome>
    <measure>Symptoms Questionnaire (CCQ)</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gene expression</measure>
    <time_frame>1 year</time_frame>
    <description>nasal gene expression signature</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Spiromax Budesonide/formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diskus Fluticasone/salmeterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiromax Budesonide/formoterol</intervention_name>
    <description>1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.</description>
    <arm_group_label>Spiromax Budesonide/formoterol</arm_group_label>
    <other_name>Spiromax® budesonide/formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diskus Fluticasone/salmeterol</intervention_name>
    <description>2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.</description>
    <arm_group_label>Diskus Fluticasone/salmeterol</arm_group_label>
    <other_name>Diskus® Fluticasone/salmeterol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40 and 80 years&#xD;
&#xD;
          -  Smoking history of &gt; 10 pack years&#xD;
&#xD;
          -  COPD patients with an FEV1 &lt; 80% predicted either or not using inhaled&#xD;
             corticosteroids.&#xD;
&#xD;
          -  At least one COPD exacerbation for which oral prednisolone had to be prescribed during&#xD;
             2 years prior to inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of asthma.&#xD;
&#xD;
          -  Exacerbation or respiratory tract infection during the last 4 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Females of childbearing potential without an efficient contraception unless they meet&#xD;
             the following definition of post-menopausal: 12 months of natural (spontaneous)&#xD;
             amenorrhea or 6 months of spontaneous amenorrhea with serum FSH &gt;40 mIU/mL or the use&#xD;
             of one or more of the following acceptable methods of contraception:&#xD;
&#xD;
               1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).&#xD;
&#xD;
               2. Hormonal contraception (implantable, patch, oral, injectable).&#xD;
&#xD;
               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/cream/suppository.&#xD;
&#xD;
               4. Continuous abstinence.&#xD;
&#xD;
          -  Periodic abstinence (e.g. calendar, ovulation, symptom-thermal, post-ovulation&#xD;
             methods) and withdrawal are not acceptable methods of contraception. Reliable&#xD;
             contraception should be maintained throughout the study and for 30 days after study&#xD;
             drug discontinuation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten van den Berge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Maarten van den Berge</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Spiromax</keyword>
  <keyword>Budesonide/formoterol</keyword>
  <keyword>COPD</keyword>
  <keyword>exacerbations</keyword>
  <keyword>SMART</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

